Brief: Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
24/06/2025 13:01
June 24 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS AND CYCLOTEK SIGN CLINICAL SUPPLY AGREEMENT FOR ¹⁶¹TB-KLK3-MAB PHASE I CLINICAL TRIAL IN AUSTRALIA RADIOPHARM THERANOSTICS LTD - PHASE 1 CLINICAL TRIAL IN PROSTATE CANCER ANTICIPATED IN 2H 2025 Source text: ID:nGNX9g9vt8 Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsNASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Radiopharm Theranostics To Meet With U.S. FDA To Align On Pivotal Phase 3 Trial Design For Rad 101 In Diagnosis Of Brain Metastases
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT CONTINUES VOLATILITY TRADING PAUSE AT 09:50 AM